This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 1
  • /
  • CHMP recommends once-weekly Sogroya to treat growt...
News

CHMP recommends once-weekly Sogroya to treat growth hormone deficiency.- Novo Nordisk.

Read time: 1 mins
Published:30th Jan 2021
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of once-weekly Sogroya (somapacitan), recommending marketing authorisation for the treatment of adults with growth hormone deficiency (AGHD).The CHMP recommends once-weekly Sogroya (somapacitan) to be indicated for the replacement of endogenous growth hormone in adults with AGHD. Sogroya (somapacitan) is a new long-acting human growth hormone therapy that is taken once a week by injection under the skin. This recommendation is based on the results from REAL 1, a clinical trial programme investigating the efficacy and safety of Sogroya (somapacitan) in adults with growth hormone deficiency.
Condition: Growth Hormone Deficiency
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights